 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...5556575859606162636465...7475» |
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. (clinicaltrials.gov) - Feb 23, 2017
P2, N=40, Recruiting, Sponsor: Greater Houston Retina Research
Trial primary completion date: Dec 2016 --> Apr 2018
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab (clinicaltrials.gov) - Feb 23, 2017
P4, N=24, Not yet recruiting, Sponsor: Southeast Clinical Research Associates, LLC
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: COVERT: Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab (clinicaltrials.gov) - Feb 16, 2017
P4, N=168, Not yet recruiting, Sponsor: St. Michael's Hospital, Toronto
- | Lucentis (ranibizumab) / Roche, Novartis
New trial: Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO (clinicaltrials.gov) - Feb 16, 2017
P=N/A, N=64, Not yet recruiting, Sponsor: Beijing Hospital
- || Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: CAN-TREAT: Canadian Treat and Extend Analysis Trial With Ranibizumab (clinicaltrials.gov) - Feb 15, 2017
P=N/A, N=580, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2016 --> Apr 2018 Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial initiation date, Trial withdrawal: CANARI: CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab (clinicaltrials.gov) - Feb 15, 2017
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=172 --> 0 | Initiation date: Dec 2015 --> Mar 2016 | Not yet recruiting --> Withdrawn
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: SMILE: Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization (clinicaltrials.gov) - Feb 8, 2017
P4, N=60, Recruiting, Sponsor: Zhongshan Ophthalmic Center, Sun Yet-san University
- ||||| Vabysmo (faricimab-svoa) / Roche
New P2 trial: STAIRWAY: Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (clinicaltrials.gov) - Feb 1, 2017
P2, N=75, Recruiting, Sponsor: Hoffmann-La Roche
- Lucentis (ranibizumab) / Roche, Novartis, Fovista (pegpleranib) / Roche, Astellas
Trial primary completion date: A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (clinicaltrials.gov) - Jan 31, 2017
P1/2, N=7, Recruiting, Sponsor: National Eye Institute (NEI)
N=172 --> 0 | Initiation date: Dec 2015 --> Mar 2016 | Not yet recruiting --> Withdrawn Trial primary completion date: Apr 2017 --> Aug 2018
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New trial: 30g vs 33g Needle for Intravitreal Injections (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=100, Recruiting, Sponsor: Wills Eye
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Trial initiation date, Combination therapy, Monotherapy: RANTA: Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy (clinicaltrials.gov) - Jan 24, 2017
P4, N=120, Recruiting, Sponsor: Aier School of Ophthalmology, Central South University
Trial primary completion date: Apr 2017 --> Aug 2018 Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Jan 2017
- Izervay (avacincaptad pegol intravitreal solution) / Astellas
Phase classification: A Study to Establish the Safety and Tolerability of Zimura (clinicaltrials.gov) - Jan 23, 2017
P2a, N=4, Completed, Sponsor: Ophthotech Corporation
Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Jan 2017 Phase classification: P2 --> P2a
- LMG324 / Novartis, Lucentis (ranibizumab) / Roche, Novartis
Trial suspension, Trial primary completion date: Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Jan 17, 2017
P1/2, N=25, Suspended, Sponsor: Alcon Research
Phase classification: P2 --> P2a Terminated --> Suspended | Trial primary completion date: May 2016 --> Feb 2016
- ||| Fumena (vorolanib) / Tyrogenex
Enrollment closed, Monotherapy, Head-to-Head: X-82 to Treat Age-related Macular Degeneration (clinicaltrials.gov) - Jan 13, 2017
P2, N=132, Active, not recruiting, Sponsor: Tyrogenex
Terminated --> Suspended | Trial primary completion date: May 2016 --> Feb 2016 Recruiting --> Active, not recruiting
- |||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Combination therapy, Monotherapy: ZIPANGU: Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety (clinicaltrials.gov) - Dec 27, 2016
P4, N=56, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Monotherapy: Macular EpiRetinal Brachytherapy Versus Lucentis (clinicaltrials.gov) - Dec 22, 2016
P4, N=363, Completed, Sponsor: King's College Hospital NHS Trust
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Fovista (pegpleranib) / Roche, Astellas
Trial termination, Combination therapy, Monotherapy: A Phase 3 Safety and Efficacy Study of Fovista (clinicaltrials.gov) - Dec 21, 2016
P3, N=619, Terminated, Sponsor: Ophthotech Corporation
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- | Fovista (pegpleranib) / Roche, Astellas
Trial termination, Combination therapy, Monotherapy: A Phase 3 Safety and Efficacy Study of Fovista (clinicaltrials.gov) - Dec 21, 2016
P3, N=627, Terminated, Sponsor: Ophthotech Corporation
Active, not recruiting --> Terminated Active, not recruiting --> Terminated
- | Fovista (pegpleranib) / Roche, Astellas
Trial termination, Combination therapy: Phase 2A Open Label Safety Study of Fovista (clinicaltrials.gov) - Dec 21, 2016
P2a, N=101, Terminated, Sponsor: Ophthotech Corporation
Active, not recruiting --> Terminated Active, not recruiting --> Terminated
- | Fovista (pegpleranib) / Roche, Astellas
Phase classification, Trial termination, Combination therapy: A 24 Month Phase 2a Open Label, Randomized Study of Avastin (clinicaltrials.gov) - Dec 21, 2016
P2a, N=64, Terminated, Sponsor: Ophthotech Corporation
Active, not recruiting --> Terminated Phase classification: P2 --> P2a | Active, not recruiting --> Terminated
- ||| Eylea (aflibercept intravitreal) / Bayer, Regeneron
Enrollment closed: TITAN: Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD (clinicaltrials.gov) - Dec 15, 2016
P4, N=236, Active, not recruiting, Sponsor: Bayer
Phase classification: P2 --> P2a | Active, not recruiting --> Terminated Recruiting --> Active, not recruiting
- |||| Fovista (pegpleranib) / Roche, Astellas
Trial primary completion date, Combination therapy, Monotherapy: A Phase 3 Safety and Efficacy Study of Fovista (clinicaltrials.gov) - Dec 14, 2016
P3, N=627, Active, not recruiting, Sponsor: Ophthotech Corporation
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2016 --> Dec 2016
- ||||| Fovista (pegpleranib) / Roche, Astellas
Enrollment closed, Trial primary completion date, Combination therapy, Monotherapy: A Phase 3 Safety and Efficacy Study of Fovista (clinicaltrials.gov) - Dec 14, 2016
P3, N=619, Active, not recruiting, Sponsor: Ophthotech Corporation
Trial primary completion date: Jul 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Dec 2016
- Ozurdex (dexamethasone intravitreal implant) / AbbVie
Trial primary completion date: DIME: Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema (clinicaltrials.gov) - Dec 14, 2016
P4, N=40, Recruiting, Sponsor: California Retina Consultants
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Dec 2016 Trial primary completion date: Dec 2016 --> Dec 2017
- sozinibercept (OPT-302) / Opthea
Enrollment closed, Combination therapy: Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis (clinicaltrials.gov) - Dec 14, 2016
P1, N=50, Active, not recruiting, Sponsor: Opthea Pty Ltd.
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Enrollment change: ERASER: Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab (clinicaltrials.gov) - Dec 14, 2016
P2/3, N=40, Active, not recruiting, Sponsor: California Retina Consultants
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=60 --> 40
- Lucentis (ranibizumab) / Roche, Novartis, Fovista (pegpleranib) / Roche, Astellas
Enrollment open: A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (clinicaltrials.gov) - Dec 6, 2016
P1/2, N=7, Recruiting, Sponsor: National Eye Institute (NEI)
Recruiting --> Active, not recruiting | N=60 --> 40 Not yet recruiting --> Recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Combination therapy: Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma (clinicaltrials.gov) - Dec 2, 2016
P1, N=40, Completed, Sponsor: Massachusetts Eye and Ear Infirmary
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New trial: Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema (clinicaltrials.gov) - Dec 1, 2016
P=N/A, N=40, Active, not recruiting, Sponsor: Lawson Health Research Institute
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: CyPov: Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy (clinicaltrials.gov) - Nov 29, 2016
P4, N=28, Not yet recruiting, Sponsor: Pusan National University Hospital
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Trial initiation date: Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen (clinicaltrials.gov) - Nov 27, 2016
P4, N=40, Active, not recruiting, Sponsor: Anders Kvanta
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Initiation date: Jun 2014 --> Oct 2014
- || Fumena (vorolanib) / Tyrogenex
Trial primary completion date, Monotherapy, Head-to-Head: X-82 to Treat Age-related Macular Degeneration (clinicaltrials.gov) - Nov 16, 2016
P2, N=132, Recruiting, Sponsor: Tyrogenex
Recruiting --> Active, not recruiting | Initiation date: Jun 2014 --> Oct 2014 Trial primary completion date: Oct 2016 --> Jan 2017
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: TIDE AMD: Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Nov 15, 2016
P4, N=40, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Oct 2016 --> Jan 2017 Trial primary completion date: Sep 2016 --> May 2017
- || Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: SAFARI: Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD (clinicaltrials.gov) - Nov 15, 2016
P4, N=124, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2016 --> May 2017 Trial primary completion date: May 2017 --> May 2018
- sozinibercept (OPT-302) / Opthea
Trial primary completion date, Combination therapy: Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis (clinicaltrials.gov) - Nov 3, 2016
P1, N=50, Recruiting, Sponsor: Opthea Pty Ltd.
Trial primary completion date: May 2017 --> May 2018 Trial primary completion date: Oct 2016 --> Jan 2017
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial, Combination therapy, Monotherapy: ZIPANGU: Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety (clinicaltrials.gov) - Nov 3, 2016
P4, N=56, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change: Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis (clinicaltrials.gov) - Nov 2, 2016
P=N/A, N=47, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2016 --> Jan 2017 Recruiting --> Completed | N=300 --> 47
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial withdrawal: Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (clinicaltrials.gov) - Oct 27, 2016
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=300 --> 47 N=40 --> 0 | Suspended --> Withdrawn
- Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Trial primary completion date: Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD (clinicaltrials.gov) - Oct 26, 2016
P4, N=110, Active, not recruiting, Sponsor: University of Cologne
N=40 --> 0 | Suspended --> Withdrawn Trial primary completion date: Dec 2016 --> Dec 2017
- |||| acrizanib (LHA510) / Novartis
Trial completion: LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration (clinicaltrials.gov) - Oct 25, 2016
P2, N=135, Completed, Sponsor: Alcon, a Novartis Company
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion (clinicaltrials.gov) - Oct 20, 2016
P4, N=30, Recruiting, Sponsor: Nagoya City University
Active, not recruiting --> Completed Trial primary completion date: Apr 2018 --> Mar 2019
- || Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD. (clinicaltrials.gov) - Oct 20, 2016
P4, N=100, Recruiting, Sponsor: Nagoya City University
Trial primary completion date: Apr 2018 --> Mar 2019 Trial primary completion date: Apr 2018 --> Mar 2019
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Enrollment change, Trial primary completion date: PROTECT: Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration (clinicaltrials.gov) - Oct 19, 2016
P1/2, N=4, Active, not recruiting, Sponsor: Leonard Feiner, MD, PhD
Trial primary completion date: Apr 2018 --> Mar 2019 Recruiting --> Active, not recruiting | N=88 --> 4 | Trial primary completion date: Nov 2017 --> Jul 2017
- ||||||| Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Trial completion: Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (clinicaltrials.gov) - Oct 18, 2016
P3, N=456, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=88 --> 4 | Trial primary completion date: Nov 2017 --> Jul 2017 Active, not recruiting --> Completed
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME (clinicaltrials.gov) - Oct 18, 2016
P2, N=100, Recruiting, Sponsor: Arshad Khanani
Active, not recruiting --> Completed Trial primary completion date: Jan 2017 --> Jan 2018
- | Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: MERIT: Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (clinicaltrials.gov) - Oct 17, 2016
P3, N=240, Not yet recruiting, Sponsor: JHSPH Center for Clinical Trials
Trial primary completion date: Jan 2017 --> Jan 2018 Initiation date: Apr 2016 --> Nov 2016
- Lucentis (ranibizumab) / Roche, Novartis
New trial: Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection (clinicaltrials.gov) - Oct 13, 2016
P=N/A, N=38, Completed, Sponsor: Fundaci
- hI-con1 (ICON-1) / Endpoint Health
Trial completion: EMERGE: Study Evaluating Intravitreal hI-con1 (clinicaltrials.gov) - Oct 12, 2016
P2, N=88, Completed, Sponsor: Iconic Therapeutics, Inc.
Initiation date: Apr 2016 --> Nov 2016 Active, not recruiting --> Completed
- || Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Noctura400 Treatment for Diabetic Retinopathy (CANDLE) (clinicaltrials.gov) - Oct 11, 2016
P=N/A, N=240, Recruiting, Sponsor: PolyPhotonix Medical
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema (clinicaltrials.gov) - Oct 5, 2016
P2, N=20, Completed, Sponsor: Retina Vitreous Associates of Florida
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed